Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label mirabegron study in children and adolescents with neurogenic detrusor overactivity using clean intermittent catheterization
MOH_2017-09-13_000080Phase 3Recruiting
- Sponsor
- Astellas Pharma
- Start
- Sep 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of mirabegron in detrusor hyperreflexia (DH), sponsored by Astellas Pharma. Primary endpoint: Efficacy of mirabegron after multiple doses in pediatric patients with neurogenic detrusor overactivity. Started Sep 2016; status: recruiting.
02
Drugs
mirabegron
03
Conditions
detrusor hyperreflexia (DH)
Beyond the preview
Go deeper on MOH_2017-09-13_000080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-09-13_000080.